Clinical laboratory and life sciences company


May 22 - UPCOMING PRESENTATION at ASCO 2017 annual meeting (Chicago, USA)

Genomac poster presentation on routine use of liquid biopsy assay for reliable detection of EGFR mutations indicating positive response or a resistence to anti-EGFR targeted biological therapy of non-small cell lung cancer (NSCLC) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place from June 2 and June 6, 2017 at the McCormick place in Chicago, Illinois, USA. The poster title is "Validation of the denaturing capillary electrophoresis (DCE) assay for non-invasive liquid biopsy in lung carcinoma: A study of concordance with the cobas EGFR mutation test v2." and the abstract number e23040.



August 18 - UPCOMING PRESENTATION at EFR 2017 Congress in Vienna, Austria

A poster titled "Circulating tumor DNA as a marker of therapeutical response to CRT in rectal cancer ?" will be presented during the 10th annual congress of the European Federation for Colorectal Cancer (EFR) in Vienna, Austria. The poster co-authored by Genomac researchers and the colleagues at the Faculty Hospital Motol, Prague is demonstrating a new direction in predicting response of certain patients to radiotherapy preceeding surgical treatment of rectal cancers using Genomac liquid biopsy approach.